Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase 1b Trial.

Steffan T Nawrocki Julian Olea Claudia Villa Celi Homa Dadrastoussi Kaijin Wu Denice Tsao-Wei Anthony R Colombo Matthew Coffey Eduardo Fernandez Hernandez Xuelian Chen Gerard J Nuovo Jennifer S Carew Ann F Mohrbacher Paul A Fields Peter Kuhn Imran Siddiqi Akil A Merchant Kevin R Kelly

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

PELA/BZ/Dex is well-tolerated and associated with anti-MM activity in a subset of responding patients, characterized by immune reprogramming and TiME changes, warranting further investigation of PELA as an immunomodulator.

Keyphrases

single cell
end stage renal disease
multiple myeloma
ejection fraction
chronic kidney disease
newly diagnosed
stem cells
rna seq
clinical trial
peritoneal dialysis
prognostic factors
study protocol
randomized controlled trial
high throughput
patient reported outcomes
phase ii
bone marrow
cell therapy